Aligos Therapeutics $83.6 million follow-on offering
Davis Polk advised the representatives of the several underwriters in connection with the $83.6 million public offering of 4,400,000 shares of common stock of Aligos Therapeutics, Inc. at $19.00 per share. Aligos’ common stock is listed on the Nasdaq Global Select Market under the symbol “ALGS.”
Aligos is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis. Aligos Therapeutics is headquartered in South San Francisco, California.
The Davis Polk corporate team included partner Alan F. Denenberg and associates Beth LeBow and Elsie Cheang. Partner Michael Farber and associate Benjamin Helfgott provided tax advice. Partner David R. Bauer and associate Daniel P. Kearney provided intellectual property advice. Counsel Marcie A. Goldstein provided FINRA advice. Associate Jason Cohen provided 1940 Act advice. Members of the Davis Polk team are based in the Northern California and New York offices.